Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 ...

Novel combination of efti with KEYTRUDA® and chemotherapy generates strong response rates across all PD-L1 expression levels in first line ...

After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in ...

A closely watched trial in Chinese patients is raising hope that ivonescimab will outperform Keytruda in a large global study ...

Merck (MRK) announced new long-term data highlighting the sustained survival benefits of Keytruda, Merck’s anti-PD-1 therapy, in treating ...

Sue McCarthy shares her experience overcoming stage 3B lung cancer, reflecting on the impact of her diagnosis. After ...

University of Queensland researcher Arutha Kulasinghe studied lung biopsies from the tumours of almost 250 patients with ...

In a small phase II trial, radiation-free treatment with pembrolizumab (Keytruda) and platinum-based chemotherapy alone ...

At a major cancer conference, Merck rolled out some showstoppers — data on drugs on which its business future may depend.

The combination of Merck’s Keytruda and Pfizer and Astellas’ Padcev reduced patients' risk of death by a whopping 50% when used before and after bladder removal surgery in those with MIBC who are not ...

Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with ...

Retail buzz around Summit Therapeutics picked up Sunday after the biotech reported what it called a first-of-its-kind result ...